News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning
BB Biotech AG reports strong NAV outperformance in Q2 2026, driven by disciplined stock selection and portfolio positioning, new investments, and revised dividend policy -